Erlotinib in routine clinical practice for first-line maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC).

Martin FaehlingJ AchenbachP StaibU SteffenH W TessenV E GaillardW Brugger

Published in: Journal of cancer research and clinical oncology (2018)

The results of this non-interventional study support the current clinical practice of erlotinib switch maintenance in EGFR-mutation-positive patients.

Keyphrases

advanced non small cell lung cancer
clinical practice
epidermal growth factor receptor
end stage renal disease
tyrosine kinase
small cell lung cancer
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
prognostic factors
stem cells